Abstract
Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered β- tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.
Keywords: Actin, Cytoskeleton, Drug resistance, Intermediate filament, MDR, Microtubule, Microtubule-targeting drugs, C-terminal amino acids, Microfilaments, microtubule-destabilizers
Anti-Cancer Agents in Medicinal Chemistry
Title:Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Volume: 13 Issue: 1
Author(s): Arun Kanakkanthara, Paul H. Teesdale-Spittle and John H. Miller
Affiliation:
Keywords: Actin, Cytoskeleton, Drug resistance, Intermediate filament, MDR, Microtubule, Microtubule-targeting drugs, C-terminal amino acids, Microfilaments, microtubule-destabilizers
Abstract: Drugs that target microtubules are a successful class of anti-cancer agents that have been in clinical use for over two decades. Acquired resistance to these drugs, however, remains a serious problem. Microtubule alterations, such as tubulin mutations and altered β- tubulin isotype expression, are prominent factors in development of resistance. Changes in actin and intermediate filament proteins can also mediate sensitivity to microtubule-targeting drugs. This review focuses on the mechanisms by which alterations in cytoskeletal proteins lead to drug resistance. This information will be helpful for improving the targeting of microtubule toxins.
Export Options
About this article
Cite this article as:
Kanakkanthara Arun, H. Teesdale-Spittle Paul and H. Miller John, Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics, Anti-Cancer Agents in Medicinal Chemistry 2013; 13 (1) . https://dx.doi.org/10.2174/1871520611307010147
DOI https://dx.doi.org/10.2174/1871520611307010147 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Aurora Kinase Inhibitors in Head and Neck Cancer
Current Topics in Medicinal Chemistry Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism Microtubule Targeting Agents: A Benchmark in Cancer Therapy
Current Drug Therapy The Use of DNA Microarrays to Investigate the Pharmacogenomics of Drug Response in Living Systems
Current Topics in Medicinal Chemistry New Targeted Therapies for Anaplastic Thyroid Cancer
Anti-Cancer Agents in Medicinal Chemistry Phage Display Applications for Molecular Imaging
Current Pharmaceutical Biotechnology Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry The Discovery of Antiangiogenic Molecules: A Historical Review
Current Pharmaceutical Design Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) The Preclinical Bases of the Rational Combination of Paclitaxel and Antiangiogenic Drugs
Clinical Cancer Drugs The Sam Domain of EphA2 Receptor and its Relevance to Cancer: A Novel Challenge for Drug Discovery?
Current Medicinal Chemistry Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Therapeutic Agents Based on DNA Sequence Specific Binding
Current Topics in Medicinal Chemistry Recent Anticancer Cytotoxic Agents
Current Medicinal Chemistry - Anti-Cancer Agents Prostate Cancer, miRNAs, Metallothioneins and Resistance to Cytostatic Drugs
Current Medicinal Chemistry Targeting mTOR Pathways in Human Malignancies
Current Pharmaceutical Design Design, Synthesis and In-Vitro Cytotoxicity of Novel Platinum (II) Complexes with Phthalate as the Leaving Group
Letters in Drug Design & Discovery Vitamin E and All-Cause Mortality: A Meta-Analysis
Current Aging Science Cancer Drug Development Using Glucose Metabolism Radiopharmaceuticals
Current Pharmaceutical Design